Incannex Healthcare (IXHL) EBITDA (2022 - 2026)

Incannex Healthcare has disclosed EBITDA across 5 years of filings, most recently posting -$4.0 million for Q1 2026.

• In Q1 2026, EBITDA rose 19.09% year-over-year to -$4.0 million; the TTM figure through Mar 2026 stood at -$25.4 million (up 2.46% YoY), while the FY2025 annual figure was -$23.8 million, up 20.81% from the prior year.
• EBITDA came in at -$4.0 million for Q1 2026 at Incannex Healthcare, up from -$7.0 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of -$3.6 million in Q4 2022 to a low of -$9.7 million in Q2 2024.
• Average EBITDA over 5 years is -$5.9 million, with a median of -$5.6 million recorded in 2024.
• The largest YoY upside for EBITDA was 37.32% in 2024 against a maximum downside of 132.33% in 2024.
• Over 5 years, EBITDA stood at -$3.6 million in 2022, then sank by 119.37% to -$8.0 million in 2023, then surged by 37.32% to -$5.0 million in 2024, then tumbled by 39.79% to -$7.0 million in 2025, then surged by 42.13% to -$4.0 million in 2026.
• Per Business Quant data, the three most recent EBITDA figures were -$4.0 million in Q1 2026, -$7.0 million in Q4 2025, and -$6.8 million in Q3 2025.